Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-2906PMID 24721645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice.

  2013cited by this paper
• Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Is tremelimumab beneficial in advanced melanoma?

  2013cited by this paper
• Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study

  2013cited by this paper
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

  2013cited by this paper
• Similarities and differences in the biogenesis, processing and lysosomal targeting between zebrafish and human pro-Cathepsin D: functional implications.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

  2013cited by this paper
• Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

  2013cited by this paper
• A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

  2012cited by this paper
• Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-&agr; or TLR-9 Agonist and GM-CSF With Peptide Vaccination

  2012cited by this paper
• The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?

  2012cited by this paper
• A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline‐containing neoadjuvant chemotherapy for breast cancer

  2012cited by this paper
• Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis.

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Cathepsin D as a potential prognostic marker for lung adenocarcinoma.

  2012cited by this paper
• Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

  2012cited by this paper
• Transcriptome Profiling of Whole Blood Cells Identifies PLEK2 and C1QB in Human Melanoma

  2011cited by this paper
• Protein kinase-regulated expression and immune function of thioredoxin reductase 1 in mouse macrophages.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins

  2011cited by this paper
• T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.

  2011cited by this paper
• A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

  2011cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer

  2010cited by this paper
• Gene expression profiling of peripheral blood cells for early detection of breast cancer

  2010cited by this paper
• Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

  2010cited by this paper
• IRAK-M regulation and function in host defense and immune homeostasis

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

  2010cited by this paper
• Clinical development of the anti-CTLA-4 antibody tremelimumab.

  2010influential reference
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009cited by this paper
• Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease.

  2009cited by this paper
• Differential Role for CD80 and CD86 in the Regulation of the Innate Immune Response in Murine Polymicrobial Sepsis

  2009cited by this paper
• Novel Blood-Based, Five-Gene Biomarker Set for the Detection of Colorectal Cancer

  2008cited by this paper
• The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

  2008cited by this paper
• Circulating microRNAs as stable blood-based markers for cancer detection

  2008cited by this paper
• Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

  2007cited by this paper
• Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86

  2004cited by this paper
• Stabilization of mRNA expression in whole blood samples.

  2002cited by this paper
• Regulation of Cell Surface Expression of CTLA-4 by Secretion of CTLA-4-Containing Lysosomes Upon Activation of CD4+ T Cells1

  2000cited by this paper

• An attention-based mRNA transformer network for accurate prediction of melanoma response to immune checkpoint inhibitors

  2025cites this paper
• Lp-PLA2 in the cancer landscape: From molecular mechanisms to therapeutic potential (Review)

  2025cites this paper
• A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications

  2025cites this paper
• Mendelian randomization study of the association between cathepsins and melanoma

  2024cites this paper
• Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma

  2024cites this paper
• Combination of theoretical analysis and experiments: Exploring the role of PLA2G7 in human cancers, including renal cancer

  2024cites this paper
• Phospholipase PLA2G7 is complementary to GPX4 in mitigating punicic-acid-induced ferroptosis in prostate cancer cells

  2024cites this paper
• IL-1 receptor–associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy

  2023cites this paper
• IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways

  2023cites this paper
• AMU: Using mRNA Embedding in Self-Attention Network to Predict Melanoma Immune Checkpoint Inhibitor Response

  2022cites this paper
• Phosphoproteomic Analysis of the Jejunum Tissue Response to Colostrum and Milk Feeding in Dairy Calves during the Passive Immunity Period

  2022cites this paper
• Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression

  2022cites this paper
• Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma

  2021cites this paper
• Metastatic melanomas: Treatment overview

  2021cites this paper
• Dimeric Structure of the Pseudokinase IRAK3 Suggests an Allosteric Mechanism for Negative Regulation

  2020cites this paper
• SMARCA4 promotes benign skin malignant transformation into melanoma through Adherens junction signal transduction

  2020cites this paper
• Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

  2019cites this paper
• A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes

  2019cites this paper
• Lipoprotein‐associated phospholipase A2: The story continues

  2019cites this paper
• Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

  2019cites this paper
• A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy

  2018cites this paper
• Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

  2018cites this paper
• A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

  2018cites this paper
• Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

  2017cites this paper
• Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

  2017influential citation
• Systematic evaluation of immune regulation and modulation

  2017cites this paper
• Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

  2017cites this paper
• Diagnostic marker signature for esophageal cancer from transcriptome analysis

  2016cites this paper
• Immunotherapy for breast cancer: past, present, and future

  2016cites this paper
• Diverse Functions of Plasma PAF-AH in Tumorigenesis.

  2015cites this paper
• Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

  2015cites this paper
• Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies

  2015cites this paper
• Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?

  2014cites this paper
• Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer

  2014cites this paper
• IL-1 receptor–associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy

  year unknowncites this paper